<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03064568</url>
  </required_header>
  <id_info>
    <org_study_id>HSC20150554H</org_study_id>
    <nct_id>NCT03064568</nct_id>
  </id_info>
  <brief_title>Rectal Misoprostol as a Hemostatic Agent During Abdominal Myomectomy</brief_title>
  <official_title>Rectal Misoprostol as a Hemostatic Agent During Abdominal Myomectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center at San Antonio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center at San Antonio</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose is to identify if misoprostol in addition to local vasopressin decreases blood loss
      when compared to vasopressin alone, which is our current practice at this time. The study
      will be double-blinded with neither the patient nor the researcher knowing whether the
      placebo or the misoprostol was given. We will monitor patients for decrease in hemoglobin and
      hematocrit, need for transfusion, and operative time among other measures of perioperative
      morbidity to see if the addition of misoprostol makes a significant difference. We will also
      observe patients to see if there are any side effects of misoprostol that make its use
      undesirable.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 14, 2016</start_date>
  <completion_date type="Anticipated">October 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Prospective double-blinded study completed at a tertiary care center</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Randomization to treatment arm done by 3rd party. Randomization will be performed by a third party so that neither the surgeon nor patient will know which intervention was performed, and interventions will be placed in sealed, sequentially numbered, opaque envelopes. The code will only be broken at time of data analysis once all patients have been enrolled.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Surgical blood loss</measure>
    <time_frame>Intraoperative</time_frame>
    <description>Estimated blood loss during surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Febrile morbiditiy</measure>
    <time_frame>24 hours postop</time_frame>
    <description>Evidence of fever or infection postoperatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for blood transfusion</measure>
    <time_frame>intraoperative to 24 hours postoperative</time_frame>
    <description>Patient requirement of blood transfusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain score</measure>
    <time_frame>24 hours postop</time_frame>
    <description>Assessment of patient subjective pain score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication side-effects</measure>
    <time_frame>24 hours postop</time_frame>
    <description>Surveillance for any adverse side effects from misoprostol</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Myomectomy; Surgical Blood Loss</condition>
  <arm_group>
    <arm_group_label>Misoprostol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive misoprostol 400mcg per rectum 30 minutes preoperatively.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive identical inert tablets per rectum 30 minutes preoperatively.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol 100Mcg Tab</intervention_name>
    <arm_group_label>Misoprostol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female age 20-50 y/o who plan to undergo abdominal myomectomy for symptomatic
             myomatous uterus

        Exclusion Criteria:

          -  Patient with contraindication to misoprostol or vasopressin, personal history or
             cardiac or pulmonary disease, history of prior myomectomy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Patient must have a uterus to participate</gender_description>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sheena M Rippentrop, MD</last_name>
    <phone>210-567-4924</phone>
    <email>rippentrop@uthscsa.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Patricia Gutierrez</last_name>
    <phone>210-567-1924</phone>
    <email>gutierrezp4@uthscsa.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>St. Lukes Baptist Hospital</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheena Rippentrop, MD</last_name>
      <phone>210-567-4924</phone>
      <email>rippentrop@uthscsa.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janet McCarthy</last_name>
      <phone>210-743-6450</phone>
      <email>janet.mccarthy@uhs-sa.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheena Rippentrop, MD</last_name>
      <phone>210-567-4924</phone>
      <email>rippentrop@uthscsa.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 22, 2017</study_first_submitted>
  <study_first_submitted_qc>February 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 27, 2017</study_first_posted>
  <last_update_submitted>February 27, 2018</last_update_submitted>
  <last_update_submitted_qc>February 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myomectomy, Misoprostol, Vasopressin, Blood loss</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Blood Loss, Surgical</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
    <mesh_term>Hemostatics</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

